Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90

A prevalent characteristic of solid tumors is intra-tumoral hypoxia. Hypoxia-inducible factor 1α (HIF1α) predominantly mediates the adaptive response to O(2) oscillation and is linked to multiple malignant hallmarks. Here we describe a strategy to robustly target HIF1α by dual inhibition of CDK(s) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shuai, Zhou, Lanlan, Dicker, David T., Lev, Avital, Zhang, Shengliang, Ross, Eric, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536770/
https://www.ncbi.nlm.nih.gov/pubmed/34686682
http://dx.doi.org/10.1038/s41598-021-00150-8
_version_ 1784588093294116864
author Zhao, Shuai
Zhou, Lanlan
Dicker, David T.
Lev, Avital
Zhang, Shengliang
Ross, Eric
El-Deiry, Wafik S.
author_facet Zhao, Shuai
Zhou, Lanlan
Dicker, David T.
Lev, Avital
Zhang, Shengliang
Ross, Eric
El-Deiry, Wafik S.
author_sort Zhao, Shuai
collection PubMed
description A prevalent characteristic of solid tumors is intra-tumoral hypoxia. Hypoxia-inducible factor 1α (HIF1α) predominantly mediates the adaptive response to O(2) oscillation and is linked to multiple malignant hallmarks. Here we describe a strategy to robustly target HIF1α by dual inhibition of CDK(s) and heat shock protein 90 (HSP90). We show that CDK1 may contribute to HSP90-mediated HIF1α stabilization. CDK1 knockdown enhances the decrease of HIF1α by HSP90 inhibition. Dual inhibition of CDK1 and HSP90 significantly increases apoptosis and synergistically inhibits cancer cell viability. Similarly, targeting CDK4/6 using FDA-approved inhibitors in combination with HSP90 inhibition shows a class effect on HIF1α inhibition and cancer cell viability suppression not only in colorectal but also in various other cancer types, including Rb-deficient cancer cells. Dual inhibition of CDK4/6 and HSP90 suppresses tumor growth in vivo. In summary, combined targeting of CDK(s) (CDK1 or CDK4/6) and HSP90 remarkably inhibits the expression level of HIF1α and shows promising anti-cancer efficacy with therapeutic potential.
format Online
Article
Text
id pubmed-8536770
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85367702021-10-25 Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90 Zhao, Shuai Zhou, Lanlan Dicker, David T. Lev, Avital Zhang, Shengliang Ross, Eric El-Deiry, Wafik S. Sci Rep Article A prevalent characteristic of solid tumors is intra-tumoral hypoxia. Hypoxia-inducible factor 1α (HIF1α) predominantly mediates the adaptive response to O(2) oscillation and is linked to multiple malignant hallmarks. Here we describe a strategy to robustly target HIF1α by dual inhibition of CDK(s) and heat shock protein 90 (HSP90). We show that CDK1 may contribute to HSP90-mediated HIF1α stabilization. CDK1 knockdown enhances the decrease of HIF1α by HSP90 inhibition. Dual inhibition of CDK1 and HSP90 significantly increases apoptosis and synergistically inhibits cancer cell viability. Similarly, targeting CDK4/6 using FDA-approved inhibitors in combination with HSP90 inhibition shows a class effect on HIF1α inhibition and cancer cell viability suppression not only in colorectal but also in various other cancer types, including Rb-deficient cancer cells. Dual inhibition of CDK4/6 and HSP90 suppresses tumor growth in vivo. In summary, combined targeting of CDK(s) (CDK1 or CDK4/6) and HSP90 remarkably inhibits the expression level of HIF1α and shows promising anti-cancer efficacy with therapeutic potential. Nature Publishing Group UK 2021-10-22 /pmc/articles/PMC8536770/ /pubmed/34686682 http://dx.doi.org/10.1038/s41598-021-00150-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhao, Shuai
Zhou, Lanlan
Dicker, David T.
Lev, Avital
Zhang, Shengliang
Ross, Eric
El-Deiry, Wafik S.
Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
title Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
title_full Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
title_fullStr Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
title_full_unstemmed Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
title_short Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
title_sort anti-cancer efficacy including rb-deficient tumors and vhl-independent hif1α proteasomal destabilization by dual targeting of cdk1 or cdk4/6 and hsp90
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536770/
https://www.ncbi.nlm.nih.gov/pubmed/34686682
http://dx.doi.org/10.1038/s41598-021-00150-8
work_keys_str_mv AT zhaoshuai anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90
AT zhoulanlan anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90
AT dickerdavidt anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90
AT levavital anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90
AT zhangshengliang anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90
AT rosseric anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90
AT eldeirywafiks anticancerefficacyincludingrbdeficienttumorsandvhlindependenthif1aproteasomaldestabilizationbydualtargetingofcdk1orcdk46andhsp90